National Coverage DeterminationClinical Laboratory

CMS Transmittal R13849CP: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for October 2026…

CMS-T-R13849CP

Document details

Document type
National Coverage Determination
Issuing body
Centers for Medicare & Medicaid Services
Document ID
CMS-T-R13849CP
Published
July 3, 2026
Effective date
October 5, 2026
MAC region
National

Summary

CMS is updating the Laboratory NCD Edit Software effective October 5, 2026, to reflect changes in National Coverage Determinations for lab services. Billing teams must review updated NCD edits in thei

Lab NCD edit software updates take effect Oct 5, 2026.

Affected specialty

Clinical Laboratory alerts →

Source document

https://www.cms.gov/medicare/regulations-guidance/transmittals/2026-transmittals/r13849cp

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

CMS Transmittal R13855CP: July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…

Policy CMS-T-R13855CP · Clinical Laboratory

Critical

This transmittal implements the July 2026 quarterly update to the Clinical Laboratory Fee Schedule (CLFS), effective July 6, 2026. Billing teams must update their lab fee schedule tables to reflect th

View alert

LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — WPS

Policy LCD-L39044 · Clinical Laboratory

High

The LCD L39044 focuses on coverage for molecular syndromic panels for infectious disease pathogen identification. As a final LCD, it is currently active and will be effective starting June 25, 2026, i

View alert

LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-L40272 · Clinical Laboratory

Critical

LCD L40272 establishes coverage criteria for MolDX biomarker testing in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), ef

View alert

LCD L40199 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS Administrators

Policy LCD-L40199 · Clinical Laboratory

Critical

LCD L40199 establishes coverage criteria for MolDX biomarker testing in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), ef

View alert